We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Swiss-headquartered Addex Therapeutics has announced it will lead a consortium to develop small molecule negative allosteric modulators (NAMs) indicated to reduce fear memory in post-traumatic stress disorder (PTSD).